CTLA4 and pancreatic adenocarcinoma: Interestingly, in the murine pancreatic adenocarcinoma model Panc02.OVA with high susceptibility to ICI, tumor-intrinsic MLKL deficiency did not impact anti-CTLA-4-mediated tumor control and had only minor negative effects on tumor-bearing mice undergoing anti-PD-1 monotherapy (online supplemental figure S2C–E).